Periscope Capital Inc. bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC – Free Report) during the 3rd quarter, HoldingsChannel.com reports. The firm bought 323,408 shares of the company’s stock, valued at approximately $3,488,000.
Separately, Rangeley Capital LLC lifted its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 52.8% in the first quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock valued at $647,000 after purchasing an additional 21,156 shares in the last quarter.
Oaktree Acquisition Corp. III Life Sciences Stock Performance
Shares of NASDAQ OACC opened at $10.71 on Monday. Oaktree Acquisition Corp. III Life Sciences has a one year low of $10.50 and a one year high of $10.93. The business has a 50-day moving average price of $10.74 and a two-hundred day moving average price of $10.70.
Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.02) earnings per share for the quarter.
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised Oaktree Acquisition Corp. III Life Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Hold rating. Based on data from MarketBeat, Oaktree Acquisition Corp. III Life Sciences currently has an average rating of “Hold”.
View Our Latest Stock Report on Oaktree Acquisition Corp. III Life Sciences
Oaktree Acquisition Corp. III Life Sciences Company Profile
Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) formed to pursue a business combination with a company in the life sciences sector. Its potential transactions could include a merger, acquisition, or similar combination. The company was sponsored by Oaktree Capital Management. As a SPAC, it did not have its own operating business or sell products and services; its intended role was to identify and combine with a business in its target sector.
See Also
- Five stocks we like better than Oaktree Acquisition Corp. III Life Sciences
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Want to see what other hedge funds are holding OACC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC – Free Report).
Receive News & Ratings for Oaktree Acquisition Corp. III Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oaktree Acquisition Corp. III Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
